• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

News & Events

  • Print
  • Share
  • E-mail

Public Calendar: September 27 - October 1, 2010

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the Federal Government.

September 27 - October 1, 2010
FDA Official and TitleDateLocationOther FDA ParticipantsNon-FDA ParticipantsSubject
Margaret A. Hamburg, M.D., Commissioner of Food and Drugs9/27/10Berlin, Germany Murray Lumpkin N/A Keynote address at Organization for Economic Cooperation and Development Workshop on Better Health Through Biomedicine Innovative Governance
Joshua M. Sharfstein, M.D., Principal Deputy Commissioner of Food and Drugs9/30/10Washington, DCN/AMembers of SubcommitteeTylenol/Johnson & Johnson
Joshua M. Sharfstein, M.D., Principal Deputy Commissioner of Food and Drugs10/1/10Austin, TXN/AAttendees at ConferenceCouncil for Responsible Nutrition Annual Conference 
Russell Abbott, Deputy Commissioner for Administration9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Dara Corrigan, Associate Commissioner for Regulatory Affairs9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Lawrence Deyton, M.S.P.H., M.D., Director, Center for Tobacco Products9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
David Dorsey, J.D., Acting Deputy Commissioner for Policy, Planning, and Budget9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Bernadette Dunham, D.V.M., Ph.D., Director, Center for Veterinary Medicine9/30/10Rockville, MDN/AJoel Newman (American Feed Industry Association)Quarterly Meeting
Jesse Goodman, M.D., M.P.H., Chief Scientist and Deputy Commissioner for Science and Public Health9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Michael M. Landa, Acting Director, Center for Food Safety and Applied Nutrition9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Murray M. Lumpkin, M.D., Deputy Commissioner for International Programs9/27/10-10/1/10 N/AN/AN/ANo Significant Meetings
Beth Martino, Associate Commissioner for External Affairs9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Karen Midthun, M.D., Director, Center for Biologics Evaluation and Research9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health9/28/10San Franciso, CAN/ASeveral Representatives from Stanford UniversityMedical Devices
Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health9/30/10Silver Spring, MDN/ASusan Alpert  (Medtronic)Medical Devices
Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health10/1/10 Silver Spring, MD N/ABrian O'Neill, Keith O'Neill (Lifesciences)Medical Devices 
William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research9/25/10-9/27/10Beijing, ChinaWeida TongN/ASpeech at the 60th Anniversary Celebration of the Chinese FDA and a joint workshop with the Chinese National Center for Safety Evaluation of Drugs, NICPBP and the International Life Science Institute/Health and Environmental Sciences Institute
William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research9/28/10Beijing, ChinaWeida Tong, Christopher Hickey, other FDA employees in Beijing Office N/A Meeting with colleagues in the FDA Beijing Office 
Michael R. Taylor, J.D., Deputy Commissioner for Foods, Office of Foods9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Ralph Tyler, J.D., Chief Counsel9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Jill Hartzler Warner, J.D., Acting Associate Commissioner for Special Medical Programs9/27/10-10/1/10N/AN/AN/ANo Significant Meetings
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research9/28/10-9/29/10Bethesda, MDDeborah Autor, Helen Winkle, Jayne Ware, Elizabeth GiaquintoDaniel Feldman (Leadership Performance Solutions, Inc.); G.K. Raju (Light Pharma Inc.)Vision for CDER Drug Quality
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research10/1/10 Washington, DCMichele MitalN/ARepublican Study Committee; Drug Regulation Briefing